Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05272384
Title Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

Hodgkin's lymphoma

B-cell lymphoma

diffuse large B-cell lymphoma

non-Hodgkin lymphoma


Decitabine and Cedazuridine + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.